cas 6636-55-1|| where to buy Methyl 6-chloro-2-pyridinecarboxylate

Produktname:Methyl 6-chloro-2-pyridinecarboxylate

IUPAC Name:methyl 6-chloropyridine-2-carboxylate

Packungseinheit	Verfügbarer Vorrat	Preis($)
CM174006-100g	in stock	ǶȺ
CM174006-500g	in stock	ƿȺũ

Nur für den Einsatz in Forschung und Entwicklung..

Anfrage-Formular

Chemische Bezeichnung

CAS-Nummer

Menge*

Erforderliche Spezifikationen*
(Gehalt %, Materialqualität etc.)

Name des Ansprechpartners*

E-Mail des Ansprechpartners*

Meanwhile I'd like to create a registered account on CHEMENU.COM with the above email.

I'd like to receive emails related to products with similar structures to 6636-55-1 regularly via the above email.

Zusätzliche Hinweise

Verification code*

refresh

: CAS-Nr.:6636-55-1; Molekulare Formel:C7H6ClNO2; Schmelzpunkt:-; SMILES-Code:O=C(C1=NC(Cl)=CC=C1)OC; Dichte:

: Katalognummer:CM174006; Molekulargewicht:171.58; Siedepunkt:; Mdl-Nr.:MFCD00155391; Lagerung:Store at 2-8°C.

: Pyridines; Pyridine is a six-membered heterocyclic compound containing one nitrogen heteroatom. Pyridine and piperidine are the most frequently occurring heterocyclic building blocks in drug molecules. According to incomplete statistics, there are currently more than 180 drugs containing pyridine or piperidine structure that have been marketed, nearly 1/5 of the drugs approved for marketing in recent years contain these two structures.; Pyridine | C5H5N | Pyridine Supplier/Distributor/Manufacturer - Chemenu; Pyridine,Pyridine Wholesale,Pyridine for Sale,Pyridine Supplier,Pyridine Distributor,Pyridine Manufacturer; Pyridine is a basic heterocyclic organic compound with the chemical formula C5H5N. It is structurally related to benzene, with one methine group (=CH−) replaced by a nitrogen atom. It is a highly flammable, weakly alkaline, water-miscible liquid with a distinctive, unpleasant fish-like smell.

: Vorasidenib; Servier presented the latest clinical data on the IDH1/2 inhibitor vorasidenib (AG-881) in the treatment of IDH-mutated diffuse glioma at the 28th Annual Meeting of the Society of Neuro-Oncology (SNO). Blinded independent radiology committee evaluation showed that vorasidenib significantly reduced tumor growth and not only preserved the patient's quality of life, but also stabilized neurocognitive function and controlled epilepsy. Based on these results, the company plans to submit a new drug application for vorasidenib to the U.S. FDA by the end of 2023 for the treatment of IDH-mutated diffuse glioma. Vorasidenib is an oral, brain-penetrating and selective dual inhibitor under development that can inhibit mutated IDH1/2 proteins and is a potential "first-in-class" drug. It has received breakthrough therapy designation from the FDA.
Chemenu has been working to develop more compounds for drug discovery. Here are the building blocks we can provide.